Researchers identify key gene that may be a marker of breast cancer metastasisApril 19, 2007Research focuses on aggressive breast cancer cells that resist anti-estrogen therapy Researchers at Fox Chase Cancer Center have identified an important gene involved in the spread of breast cancer that has developed resistance to long-term estrogen deprivation. The discovery was reported today in an oral presentation during the 97th Annual Meeting of the American Association for Cancer Research in Los Angeles. The gene may prove to be a useful marker for predicting which patients have the greatest risk of breast cancer recurrence so their doctors can offer the most appropriate treatment plan. The research focused on breast cancer cells that had grown resistant to a class of anti-hormone drugs called aromatase inhibitors. AIs shut down an enzyme, aromatase, that lets the body produce estrogen outside the ovaries. These drugs represent one of the newest, most effective forms of hormone therapy for postmenopausal women whose breast cancer tests positive for estrogen receptors, which means that estrogen in the body fuels the growth of cancer cells.
"Unfortunately, one of the drawbacks to extended use of an AI may be that some of the cancer cells develop resistance to the drug and are able to grow and spread independent of estrogen," said Fox Chase Cancer Center biochemist Joan S. Lewis-Wambi, Ph.D, who presented the results of the study of aggressive AI-resistant breast cancer cells. "Our laboratory has developed several AI-resistant breast cancer cell lines and have found that these cells are very invasive compared to AI-sensitive breast cancer cells," she explained. "Analyses of gene activity in these AI-resistant cells have shown that they express high levels of genes associated with invasiveness and metastasis." The researchers found, however, that they could reverse this aggressive behavior by using molecules called "small interfering RNAs" to knock out the gene called CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6). "Overall, these findings identify CEACAM6 as a unique mediator of the aggressiveness and spread of AI-resistant breast cancer," Lewis-Wambi said. \\\ Fox Chase Cancer Center | |||||||||||||||||||||
|
Related Breast Cancer News Articles Duke chemists synthesize promising anti-cancer product Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected. Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter. Targeted radiation therapy can control limited cancer spread Precisely targeted radiation therapy can eradicate all evidence of disease in selected patients with cancer that has spread to only a few sites, suggests the first published report from an ongoing clinical trial. Risk assessment plays key role in long-term treatment of breast cancer Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence. First step towards switching off breast cancer and leukaemia Australian scientists have identified a way to 'switch off' a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia. Exercise Pill is No Replacement for Exercise Recently, researchers at the Salk Institute for Biological Studies, a research organization focused on biology and its relation to health, published a study in the journal Cell on the results of a substance that increased exercise endurance without daily exertion when tested in mice. Perceived discrimination affects screening rates Minority men and women who perceived discrimination from their health care providers were less likely to be screened for colorectal or breast cancer, according to a report in the August issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research. Breast cancer confessions: The emotional work of disclosing a diagnosis Women diagnosed with breast cancer shoulder the emotional burden of disclosing their diagnosis to loved ones, managing the feelings of others at precisely the time when they need support themselves, according to research to be presented at the annual meeting of the American Sociological Association (ASA). Improved estrogen reception may sharpen fuzzy memory Estrogen treatments may sharpen mental performance in women with certain medical conditions, but University of Florida researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs. Hip bone density helps predict breast cancer risk Measuring a woman's bone mineral density can provide additional information that may help more accurately determine a woman's risk of developing breast cancer. More Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||